Advertisement
Screener

GILEAD SCIENCES, INC. (GILD) Increase (Decrease) in Deferred Income Taxes

GILEAD SCIENCES, INC. Increase (Decrease) in Deferred Income Taxes

GILEAD SCIENCES, INC. (GILD) reported Increase (Decrease) in Deferred Income Taxes of $116.00 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-23.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInDeferredIncomeTaxes · last filed 2022-02-23

  • GILEAD SCIENCES, INC. increase (decrease) in deferred income taxes for the quarter ending 2016-12-31 was $24.00M.
  • GILEAD SCIENCES, INC. increase (decrease) in deferred income taxes for the quarter ending 2016-09-30 was -$21.00M, a 111.54% decline year-over-year.
  • GILEAD SCIENCES, INC. increase (decrease) in deferred income taxes for the quarter ending 2016-06-30 was $131.00M, a 5.76% decline year-over-year.
  • GILEAD SCIENCES, INC. increase (decrease) in deferred income taxes for the quarter ending 2016-03-31 was -$15.00M, a 112.40% decline year-over-year.
  • GILEAD SCIENCES, INC. increase (decrease) in deferred income taxes for fiscal 2021 was $116.00M, a 45.79% decline from fiscal 2020.
  • GILEAD SCIENCES, INC. increase (decrease) in deferred income taxes for fiscal 2020 was $214.00M, a 89.80% decline from fiscal 2019.
  • GILEAD SCIENCES, INC. increase (decrease) in deferred income taxes for fiscal 2019 was $2.10B.
  • GILEAD SCIENCES, INC. increase (decrease) in deferred income taxes for fiscal 2018 was -$289.00M, a 452.44% decline from fiscal 2017.
Period endIncrease (Decrease) in Deferred Income Taxes 3 monthIncrease (Decrease) in Deferred Income Taxes 3 month as first filedIncrease (Decrease) in Deferred Income Taxes 6 monthIncrease (Decrease) in Deferred Income Taxes 6 month as first filedIncrease (Decrease) in Deferred Income Taxes 9 monthIncrease (Decrease) in Deferred Income Taxes 9 month as first filedIncrease (Decrease) in Deferred Income Taxes 12 monthIncrease (Decrease) in Deferred Income Taxes 12 month as first filed
2021-12-31$116.00M
10-K · filed 2022-02-23
2020-12-31$214.00M
10-K · filed 2022-02-23
2019-12-31$2.10B
10-K · filed 2022-02-23
2018-12-31-$289.00M
10-K · filed 2021-02-25
2017-12-31$82.00M
10-K · filed 2020-02-25
2016-12-31$24.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26
$3.00M
derived: sum of 2 quarters · filed 2019-02-26
$134.00M
derived: sum of 3 quarters · filed 2019-02-26
$119.00M
10-K · filed 2019-02-26
2016-09-30-$21.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07
$110.00M
derived: sum of 2 quarters · filed 2016-11-07
$95.00M
10-Q · filed 2016-11-07
$46.00M
derived: sum of 4 quarters · filed 2018-02-27
2016-06-30$131.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05
$116.00M
10-Q · filed 2016-08-05
$67.00M
derived: sum of 3 quarters · filed 2018-02-27
$249.00M
derived: sum of 4 quarters · filed 2018-02-27
2016-03-31-$15.00M
10-Q · filed 2016-05-06
-$64.00M
derived: sum of 2 quarters · filed 2018-02-27
$118.00M
derived: sum of 3 quarters · filed 2018-02-27
$257.00M
derived: sum of 4 quarters · filed 2018-02-27
2015-12-31-$49.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27
$133.00M
derived: sum of 2 quarters · filed 2018-02-27
$272.00M
derived: sum of 3 quarters · filed 2018-02-27
$393.00M
10-K · filed 2018-02-27
2015-09-30$182.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07
$321.00M
derived: sum of 2 quarters · filed 2016-11-07
$442.00M
10-Q · filed 2016-11-07
$611.00M
derived: sum of 4 quarters · filed 2017-02-27
2015-06-30$139.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05
$260.00M
10-Q · filed 2016-08-05
$429.00M
derived: sum of 3 quarters · filed 2017-02-27
$443.00M
derived: sum of 4 quarters · filed 2017-02-27
2015-03-31$121.00M
10-Q · filed 2016-05-06
$290.00M
derived: sum of 2 quarters · filed 2017-02-27
$304.00M
derived: sum of 3 quarters · filed 2017-02-27
$354.00M
derived: sum of 4 quarters · filed 2017-02-27
2014-12-31$169.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27
$183.00M
derived: sum of 2 quarters · filed 2017-02-27
$233.00M
derived: sum of 3 quarters · filed 2017-02-27
$236.00M
10-K · filed 2017-02-27
2014-09-30$14.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04
$64.00M
derived: sum of 2 quarters · filed 2015-11-04
$67.00M
10-Q · filed 2015-11-04
$67.06M
10-Q · filed 2014-11-05
$152.60M
derived: sum of 4 quarters · filed 2016-02-24
2014-06-30$50.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05
$53.00M
10-Q · filed 2015-08-05
$53.54M
10-Q · filed 2014-08-04
$138.60M
derived: sum of 3 quarters · filed 2016-02-24
$160.97M
derived: sum of 4 quarters · filed 2016-02-24
2014-03-31$3.00M
10-Q · filed 2015-05-08
$3.32M
10-Q · filed 2014-05-07
$88.60M
derived: sum of 2 quarters · filed 2016-02-24
$110.97M
derived: sum of 3 quarters · filed 2016-02-24
$140.30M
derived: sum of 4 quarters · filed 2016-02-24
2013-12-31$85.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24
$107.97M
derived: sum of 2 quarters · filed 2016-02-24
$137.30M
derived: sum of 3 quarters · filed 2016-02-24
$98.00M
10-K · filed 2016-02-24
$98.18M
10-K · filed 2014-02-25
2013-09-30$22.37M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05
$51.70M
derived: sum of 2 quarters · filed 2014-11-05
$12.40M
10-Q · filed 2014-11-05
$72.77M
derived: sum of 4 quarters · filed 2015-02-25
2013-06-30$29.33M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-04
-$9.97M
10-Q · filed 2014-08-04
$50.40M
derived: sum of 3 quarters · filed 2015-02-25
$50.99M
derived: sum of 4 quarters · filed 2015-02-25
2013-03-31-$39.30M
10-Q · filed 2014-05-07
$21.07M
derived: sum of 2 quarters · filed 2015-02-25
$21.66M
derived: sum of 3 quarters · filed 2015-02-25
$51.08M
derived: sum of 4 quarters · filed 2015-02-25
2012-12-31$60.37M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-25
$60.97M
derived: sum of 2 quarters · filed 2015-02-25
$90.39M
derived: sum of 3 quarters · filed 2015-02-25
$39.00M
10-K · filed 2015-02-25
$39.39M
10-K · filed 2013-02-27
2012-09-30$592.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-31
$30.01M
derived: sum of 2 quarters · filed 2013-10-31
-$21.37M
10-Q · filed 2013-10-31
-$42.02M
derived: sum of 4 quarters · filed 2014-02-25
2012-06-30$29.42M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01
-$21.97M
10-Q · filed 2013-08-01
-$42.61M
derived: sum of 3 quarters · filed 2014-02-25
-$46.02M
derived: sum of 4 quarters · filed 2014-02-25
2012-03-31-$51.38M
10-Q · filed 2013-05-08
-$72.03M
derived: sum of 2 quarters · filed 2014-02-25
-$75.44M
derived: sum of 3 quarters · filed 2014-02-25
-$94.90M
derived: sum of 4 quarters · filed 2014-02-25
2011-12-31-$20.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25
-$24.05M
derived: sum of 2 quarters · filed 2014-02-25
-$43.52M
derived: sum of 3 quarters · filed 2014-02-25
-$64.06M
10-K · filed 2014-02-25
2011-09-30-$3.41M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06
-$22.87M
derived: sum of 2 quarters · filed 2012-11-06
-$43.41M
10-Q · filed 2012-11-06
-$12.85M
derived: sum of 4 quarters · filed 2013-02-27
2011-06-30-$19.46M
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-01
-$40.01M
10-Q · filed 2012-08-01
-$9.44M
derived: sum of 3 quarters · filed 2013-02-27
2011-03-31-$20.55M
10-Q · filed 2012-05-04
$10.02M
derived: sum of 2 quarters · filed 2013-02-27
2010-12-31$30.57M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27
-$12.15M
10-K · filed 2013-02-27
2010-09-30-$42.72M
10-Q · filed 2011-11-04
2009-12-31$42.01M
10-K · filed 2012-02-23

Similar stocks

Stock NameCountryMarket CapPE Ratio
AMGEN INC (AMGN)United States$219.567B22.39
Moderna, Inc. (MRNA)United States$77.819B-8.86
Revolution Medicines, Inc. (RVMD)United States$42.805B-22.69
BIOGEN INC. (BIIB)United States$33.427B19.60
EXELIXIS, INC. (EXEL)United States$14.358B16.15
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31